Stocks Industrials TMO
NYSE · IndustrialsThermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific Inc. brought in $46.3B of revenue over the twelve months to June 27, 2026, up 7.2% from a year earlier. Net income was $7B, a net margin of 15.0%. Operating cash flow minus capital spending left $6.3B of free cash flow in fiscal 2025. At June 27, 2026 it held $4.1B in cash against $42.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.
Key facts about Thermo Fisher Scientific Inc.
- Net worth
- Thermo Fisher Scientific Inc. has a market value (market cap) of $243.3B at the latest share price, and shareholders' equity of $52.7B on its balance sheet at June 27, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $44.6B (+3.9% year on year), with net income of $6.7B. Over the 12 months to June 27, 2026: revenue $46.3B, net income $7B.
- Cash flow
- In fiscal 2025 operations brought in $7.8B of cash; after $1.5B of capital spending, free cash flow was $6.3B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 31, 2026 and covers the period to June 27, 2026. Open on SEC EDGAR
- Next earnings report
- Thermo Fisher Scientific Inc.'s next report is expected around October 21, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Thermo Fisher Scientific Inc. declared dividends of $1.72 per share in fiscal 2025, a yield of 0.26% at the current price.
What Thermo Fisher Scientific Inc. does
Thermo Fisher Scientific produces analytical instruments, laboratory equipment, consumables, reagents, and software for scientific research and healthcare. It also provides clinical research and contract drug manufacturing services. Its customers include academic research institutions, government laboratories, pharmaceutical companies, biotechnology firms, and clinical diagnostic labs. Its shares trade on NYSE under the ticker TMO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $44.6B | $6.7B | $17.74 | $6.3B |
| 2024 | $42.9B | $6.3B | $16.53 | $7.3B |
| 2023 | $42.9B | $6B | $15.45 | $6.9B |
| 2022 | $44.9B | $7B | $17.63 | $6.9B |
| 2021 | $39.2B | $7.7B | $19.46 | $6.8B |
| 2020 | $32.2B | $6.4B | $15.96 | $6.8B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TMO ranks in Industrials
Dividends
Thermo Fisher Scientific Inc. declared $1.72 per share in fiscal 2025. At the current price that is a yield of 0.26%. It paid out $636M in cash dividends, 9% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $1.72 | $636M | 9% |
| 2024 | $1.56 | $583M | 9% |
| 2023 | $1.40 | $523M | 9% |
| 2022 | $1.20 | $455M | 7% |
| 2021 | $1.04 | $395M | 5% |
| 2020 | $0.88 | $337M | 5% |
Latest SEC filings
What Thermo Fisher Scientific Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 31, 2026Quarterly report 10-Q · period to June 27, 2026Revenue rose 10% to $12B versus the same quarter last year; diluted EPS $4.68 versus $4.28.
- July 23, 2026
- June 23, 2026
- May 28, 2026
- May 26, 2026
- May 11, 2026Additional proxy material DEFA14A
- May 1, 2026Quarterly report 10-Q · period to March 28, 2026Revenue rose 6.2% to $11B versus the same quarter last year; diluted EPS $4.43 versus $3.98.
- April 30, 2026Passive stake (5% or more) SCHEDULE 13G
- April 23, 2026
- April 7, 2026
What is TMO worth? A DCF from its reported cash flow
Insider trades
What the people running Thermo Fisher Scientific Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $61.6M worth of shares in the last 90 days and bought none on the open market. Most of the selling (83%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Pettiti GianlucaPresident & COO | Soldpre-planned (10b5-1) | 400 | $245.8K |
| August 31, 2026 | Pettiti GianlucaPresident & COO | Exercised options | 3,733 | $1.2M |
| August 31, 2026 | Pettiti GianlucaPresident & COO | Soldpre-planned (10b5-1) | 3,733 | $2.3M |
| August 28, 2026 | Britt Lisa P.Sr. VP and Chief HR Officer | Shares withheld for tax | 87 | $54.1K |
| August 28, 2026 | Britt Lisa P.Sr. VP and Chief HR Officer | Shares withheld for tax | 116 | $72.2K |
| August 28, 2026 | Britt Lisa P.Sr. VP and Chief HR Officer | Shares withheld for tax | 105 | $65.6K |
| August 28, 2026 | Britt Lisa P.Sr. VP and Chief HR Officer | Shares withheld for tax | 85 | $52.9K |
| August 28, 2026 | Pettiti GianlucaPresident & COO | Shares withheld for tax | 212 | $132.1K |
Who owns TMO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.53% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 2,616 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 30,919,632 | +492,440 |
| Vanguard Capital Management LLC | 24,276,316 | -4,500 |
| State Street Corp | 16,825,879 | +94,211 |
| Fmr LLC | 14,084,488 | +3,308,052 |
| Morgan Stanley | 10,763,066 | -100,462 |
| Jpmorgan Chase & Co | 8,503,527 | +1,708,045 |
| Geode Capital Management, LLC | 8,382,401 | -25,490 |
| Franklin Resources Inc | 7,271,514 | +458,483 |
| Vanguard Portfolio Management LLC | 6,226,169 | +62,799 |
| Capital World Investors | 6,195,370 | -450,946 |
| Norges Bank | 5,087,903 | new |
| Massachusetts Financial Services Co | 2,965,714 | -47,395 |
| Capital Research Global Investors | 4,147,545 | -267,076 |
| Bank of New York Mellon Corp | 3,938,410 | +171,796 |
| Bank of America Corp | 3,895,265 | -1,638,138 |
| Royal Bank of Canada | 3,430,798 | -483,105 |
| Northern Trust Corp | 3,328,836 | -86,774 |
| Capital International Investors | 3,182,151 | -706,575 |
| Charles Schwab Investment Management Inc | 3,114,527 | +179,685 |
| Dodge & Cox | 3,054,778 | +3,029,037 |
Insiders
20 insiders reported holding 448,132 shares in total, about $294.9M at the last price.
| Holder | Shares |
|---|---|
| Casper Marc NChairman & CEO, Director | 122,669 |
| Lagarde MichelExecutive Vice President | 85,151 |
| Sperling Scott MDirector | 69,479 |
| Williamson StephenRetiring Sr. VP and CFO | 32,499 |
| Pettiti GianlucaPresident & COO | 23,216 |
| Shafer Michael DExecutive Vice President | 20,204 |
| Chai NelsonDirector | 15,316 |
| Lowery Frederick M.Executive Vice President | 15,044 |
| Britt Lisa P.Sr. VP and Chief HR Officer | 14,391 |
| Harris C MartinDirector | 9,532 |
Questions about TMO
What does Thermo Fisher Scientific Inc. do?
Thermo Fisher Scientific produces analytical instruments, laboratory equipment, consumables, reagents, and software for scientific research and healthcare. It also provides clinical research and contract drug manufacturing services. Its customers include academic research institutions, government laboratories, pharmaceutical companies, biotechnology firms, and clinical diagnostic labs. Its shares trade on NYSE under the ticker TMO.
What is Thermo Fisher Scientific Inc.'s net worth?
Thermo Fisher Scientific Inc. has a market value (market cap) of $243.3B at the latest share price, and shareholders' equity of $52.7B on its balance sheet at June 27, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Thermo Fisher Scientific Inc. profitable?
Yes. Over the twelve months to June 27, 2026 it reported net income of $7B on revenue of $46.3B, a net margin of 15.0%.
How much revenue does Thermo Fisher Scientific Inc. make?
Over the twelve months to June 27, 2026 Thermo Fisher Scientific Inc. reported revenue of $46.3B. That is 7.2% more than a year earlier.
When did Thermo Fisher Scientific Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 27, 2026. Its newest filing of any kind is the insider trade from September 29, 2026.
When is Thermo Fisher Scientific Inc.'s next earnings report?
Thermo Fisher Scientific Inc.'s next report is expected around October 21, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Thermo Fisher Scientific Inc. pay a dividend?
Yes. Thermo Fisher Scientific Inc. declared dividends of $1.72 per share in fiscal 2025, a yield of 0.26% at the current price.
Theses that mention TMO
Similar companies
Compare TMO with
Follow TMO
Get an email when Thermo Fisher Scientific Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Thermo Fisher Scientific Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.